Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-24-196209
Filing Date
2024-08-08
Accepted
2024-08-07 21:12:02
Documents
7

Document Format Files

Seq Description Document Type Size
1 424B3 d881867d424b3.htm 424B3 1009445
2 GRAPHIC g881867g0807231810110.jpg GRAPHIC 3642
3 GRAPHIC g881867g0808002555238.jpg GRAPHIC 24516
4 GRAPHIC g881867g0808002555441.jpg GRAPHIC 33924
5 GRAPHIC g881867g0808002555624.jpg GRAPHIC 21402
6 GRAPHIC g881867g0808002555941.jpg GRAPHIC 22393
7 GRAPHIC g881867g78q55.jpg GRAPHIC 83718
  Complete submission text file 0001193125-24-196209.txt   1272650
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-278810 | Film No.: 241185690
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)